FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DRREDDY

5,059.9
+7.7 (0.15%)
Updated 02:06 22/01 IST

DRREDDY Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 380,051.25 for DRREDDY
Disclaimer
100% Bullish
0% Bearish

DRREDDY Buy or Sell - Brokerage Reports

No. of reports in last year
20
No. of analysts
8
Average Consensus Forecast
4955.85
Consensus Potential
-7.45%
See DRREDDY Share Price Targets >>

DRREDDY Ratings

Long term DRREDDY rating by FrontPage users
4.5/5 (11 Ratings)
Find answers to all your questions on live DRREDDY message board: Is DRREDDY buy or sell? Should I buy DRREDDY shares? Why are DRREDDY shares falling? Should I invest in DRREDDY stock?

  1. Home
  2. DRREDDY Forum

DRREDDY Share Price Discussion


Bought #DRREDDY options - DRREDDY21JAN5050CE Avg Price 84.55
Like
Reply

Sold #DRREDDY options - DRREDDY21JAN5050CE at 83.53
Like
Reply

Bought #DRREDDY options - DRREDDY21JAN5050CE Avg Price 84.33
Like
Reply

Sold #DRREDDY options - DRREDDY21JAN5050CE at 83.05
Like
Reply

Bought #DRREDDY options - DRREDDY21JAN5050CE at 85.15
Like
Reply
D
Reputation: 3,485 • Just now

DRREDDY - chart - 2006627
#DRREDDY Chart without candles, Buyer and seller
1
Reply
R
Reputation: -13,236 • Just now

Type
Buy
Instrument
DRREDDY JAN21 5050 CE
Entry Price
₹91.5
Price@Trade
₹91.5
Target Price
₹130
Stop Price
₹64
Valid Till
Jan 22, 2021 3:20 AM
Margin
₹114,375 approx for 1250 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
DRREDDY JAN21 FUT
Entry Price
₹5,050
Price@Trade
₹5,053.95
Target Price
₹5,150
Stop Price
₹5,025
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹122,197.75 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹5,025
Net P&L
-₹3,125 (-2.56%)
Buy dr tessy
Like
Reply (2)
See all replies

Update
Trade Entered
Entry Price
₹5,050

Update
Stoploss Hit
Exit Price
₹5,025
D
Reputation: 3,485 • Just now

Type
Buy
Instrument
DRREDDY JAN21 5050 CE
Entry Price
₹87.7
Price@Trade
₹87.7
Target Price
₹115
Stop Price
₹65
Valid Till
Jan 22, 2021 3:20 AM
Margin
₹21,925 approx for 250 Qty
Status
Exited
Exit Price
₹91.9
Net P&L
+₹1,050 (+4.79%)
1
Reply (1)
See all replies

Update
Exited
Exit Price
₹91.9
Net P&L
+₹1,050 (+4.79%)
R
Reputation: 180 • Just now

Type
Sell
Instrument
DRREDDY
Entry Price
₹5,023
Price@Trade
₹5,025.05
Target Price
₹5,010
Stop Price
₹5,027
Valid Till
Jan 29, 2021 3:20 AM
Margin
₹502,300 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹5,027
Net P&L
-₹400 (-0.08%)
Like
Reply (2)
See all replies

Update
Trade Entered
Entry Price
₹5,023

Update
Stoploss Hit
Exit Price
₹5,027
B
Reputation: 8,675 • Just now
Like
Reply
P
Reputation: 5,337 • Just now
Pyramidstock in DRREDDY
Sell Dr reddy cmp 5080-90 sl 5175 tgt 5000-4940...
Like
Reply
R
Reputation: -13,236 • Just now

Type
Buy
Instrument
DRREDDY JAN21 4900 PE
Entry Price
₹46
Price@Trade
₹46
Target Price
₹100
Stop Price
₹35
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹5,750 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹35
Net P&L
-₹1,375 (-23.91%)
Like
Reply (1)
See all replies

Update
Stoploss Hit
Exit Price
₹35

🛑 **SUPER DUPER DAY END GUYS FOR US**🛑
**COFORGE 2600 TO 2535**
**DR REDDY 5100 TO 5033**
**SRF 5900 TO 5578**
**HAVELLS (BTST) - 1020 TO 1147**
**BLUEDART 4300 TO 4160**
Like
Reply
RJ ROCKET TRADES in DRREDDY
**SELL DR REDDY BELOW 5100** **TG 5090/5070/505...

**MORE FALL IN DR REDDY GUYS**
**ALMOST ALL OUR TARGETS HIT IN IT**
**5033 FROM 5100**
Like
Reply

STBT: SELL DRREDDY JAN BELOW 5070

Like
Reply
Pyramidstock in DRREDDY
Sell Dr reddy cmp 5080-90 sl 5175 tgt 5000-4940...
Like
Reply
RJ ROCKET TRADES in DRREDDY
**SELL DR REDDY BELOW 5100** **TG 5090/5070/505...

**DR REDDY AS TOLD U 2ND SUPPORT ALSO BROKEN**
**NOW ITS 5074 FROM 5100**
**T1 HIT**
**T2 ALMOST HIT**
Like
Reply

Sell Dr reddy cmp 5080-90 sl 5175 tgt 5000-4940-4850 #DRREDDY
Like
Reply
RJ ROCKET TRADES in DRREDDY
**SELL DR REDDY BELOW 5100** **TG 5090/5070/505...

**MORE FALL STARTED IN DR REDDY GUYS**
**TILL NOW 5087 FROM 5100**
T1 HIT
Like
Reply

**SELL DR REDDY BELOW 5100**
**TG 5090/5070/5050/5030**
SL 5116
Like
Reply

Type
Buy
Instrument
DRREDDY FEB21 5500 CE
Entry Price
₹110
Price@Trade
₹110
Target Price
₹160
Stop Price
₹80
Valid Till
Feb 25, 2021 3:20 AM
Margin
₹13,750 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹80
Net P&L
-₹3,750 (-27.27%)
Like
Reply (1)
See all replies

Update
Stoploss Hit
Exit Price
₹80

Type
Buy
Instrument
DRREDDY
Entry Price
₹5,115.95
Price@Trade
₹5,115.95
Target Price
₹5,140  ₹5,150
Stop Price
₹5,098
Valid Till
Jan 21, 2021 3:20 AM
Margin
₹306,957 approx for 60 Qty
Status
Stoploss Hit
Exit Price
₹5,098
Net P&L
-₹1,077 (-0.35%)
Like
Reply (2)
See all replies
Rajneesh  @Zerodhapartner
Yesterday 4:22 AM

Update
Target Extended
Price @ Update
₹5,119
Original Target
₹5,140
New Target
₹5,150
TrackerBot @trackerbot
Yesterday 5:06 AM

Update
Stoploss Hit
Exit Price
₹5,098
S
Reputation: 3,177 • Yesterday 3:00 AM

21-01-21
DRREDDY BUY JAN CE 5100 (Intraday)
only Above 120
Like
Reply (1)
See all replies
Sameer  @tradingfab
Yesterday 3:05 AM

high 123 💥💥💥🚀🚀🔥🔥🔥
D
Reputation: 3,485 • Jan 20 6:12 AM

Type
Sell
Instrument
DRREDDY JAN21 FUT
Entry Price
₹5,099.35
Price@Trade
₹5,099.35
Target Price
₹5,070
Stop Price
₹5,120
Valid Till
Jan 20, 2021 3:20 AM
Margin
₹124,802.66 approx for 125 Qty
Status
Exited
Exit Price
₹5,095.45
Net P&L
+₹487.5 (+0.39%)
1
Reply (1)
See all replies
Dharun Invester @dharun
Jan 20 6:28 AM

Update
Exited
Exit Price
₹5,095.45
Net P&L
+₹487.5 (+0.39%)
S
Reputation: 3,177 • Jan 20 6:02 AM

20-01-21
DRREDDY BUY JAN PE 5100 (Intraday)
only Above 107
Like
Reply (3)
See all replies
Sameer  @tradingfab
Jan 20 6:25 AM

LTP 109.50 💥💥💥💥💥
Sameer  @tradingfab
Jan 20 6:31 AM

LTP 110.50 💥💥💥💥💥🤑
Sameer  @tradingfab
Jan 20 6:42 AM

high 116 💥💥💥🚀🚀🤑🤑🤑✈️
D
Reputation: -8,540 • Jan 20 5:19 AM

Type
Buy
Instrument
DRREDDY JAN21 5100 PE
Entry Price
₹87.65
Price@Trade
₹87.65
Target Price
₹100
Stop Price
₹80
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹10,956.25 approx for 125 Qty
Status
Target Achieved
Exit Price
₹100
Net P&L
+₹1,543.75 (+14.09%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Jan 20 6:01 AM

Update
Target Achieved
Exit Price
₹100
N
Reputation: 2,440 • Jan 20 4:14 AM

Type
Buy
Instrument
DRREDDY JAN21 5400 CE
Entry Price
₹36.8
Price@Trade
₹36.8
Target Price
₹75
Stop Price
₹20
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹4,600 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹20
Net P&L
-₹2,100 (-45.65%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 3:26 AM

Update
Stoploss Hit
Exit Price
₹20
M
Reputation: 36,485 • Jan 20 3:21 AM

Type
Buy
Instrument
DRREDDY JAN21 FUT
Entry Price
₹5,129.95
Price@Trade
₹5,129.95
Target Price
₹5,500
Stop Price
₹5,000
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹124,219.53 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹5,000
Net P&L
-₹16,243.75 (-13.08%)
Like
Reply (1)
See all replies

Update
Stoploss Hit
Exit Price
₹5,000
V
Reputation: 8,644 • Jan 20 3:06 AM

Type
Buy
Instrument
DRREDDY JAN21 5100 CE
Entry Price
₹124  ₹124.65
Price@Trade
₹124.65
Target Price
₹152
Stop Price
₹112
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹15,581.25 approx for 125 Qty
Status
Exited
Exit Price
₹131
Net P&L
+₹793.75 (+5.09%)
Like
Reply (3)
See all replies
Vishwas K @vishwask
Jan 20 3:06 AM

Update
Entry Price Modified
Price @ Update
₹124.65
Original Entry Price
₹124
New Entry Price
₹124.65
TrackerBot @trackerbot
Jan 20 3:07 AM

Update
Trade Entered
Entry Price
₹124.65
Vishwas K @vishwask
Jan 20 3:40 AM

Update
Exited
Exit Price
₹131
Net P&L
+₹793.75 (+5.09%)
Billion Club in DRREDDY
BTST -: BUY DRREDDY ABV 5086 SL BELOW 5030 TGT ...

#DRREDDY BTST -: ONCE EXIT LONG IN DRREDDY AT 5132 BOOK PROFIT RS 5,750
1
Reply

DRREDDY - 1981444

The price has formed pole-flag pattern & is taking resistance from 50EMA in 15MINS TF.
Also, the price is facing resistance from the SUPPLY ZONE in 1HOUR TF.
Like
Reply

DRREDDY - chart - 1980979
#DRREDDY with Major Support and Resistance zones also a breakout is done
Eye on it for tomorrow
1
Reply
Like
Reply

BTST -: BUY DRREDDY ABV 5086 SL BELOW 5030 TGT 5150.-5200

1
Reply (1)
See all replies
Billion Club @100billionclub
Jan 20 2:48 AM

BTST -: ONCE EXIT LONG IN DRREDDY AT 5132 BOOK PROFIT RS 5,750

Type
Sell
Instrument
DRREDDY
Entry Price
₹5,045
Price@Trade
₹5,042.5
Target Price
₹4,990
Stop Price
₹5,100
Valid Till
Feb 19, 2021 3:20 AM
Margin
₹100,900 approx for 20 Qty
Status
Stoploss Hit
Exit Price
₹5,100
Net P&L
-₹1,100 (-1.09%)
Like
Reply (2)
See all replies
TrackerBot @trackerbot
Jan 19 4:46 AM

Update
Trade Entered
Entry Price
₹5,045
TrackerBot @trackerbot
Jan 19 8:29 AM

Update
Stoploss Hit
Exit Price
₹5,100
H
Reputation: 4,635 • Jan 19 3:14 AM

Type
Sell
Instrument
DRREDDY JAN21 FUT
Entry Price
₹5,102
Price@Trade
₹5,097.2
Target Price
₹5,000  ₹4,950
Stop Price
₹5,200
Valid Till
Jan 19, 2021 3:20 AM
Margin
₹123,337.25 approx for 125 Qty
Status
Exited
Exit Price
₹5,094.2
Net P&L
+₹975 (+0.79%)
Like
Reply (3)
See all replies
Hitesh @hitesh-ryosrGGPD
Jan 19 3:14 AM

Update
Target Extended
Price @ Update
₹5,099
Original Target
₹5,000
New Target
4950.0
TrackerBot @trackerbot
Jan 19 3:15 AM

Update
Trade Entered
Entry Price
₹5,102
Hitesh @hitesh-ryosrGGPD
Jan 19 3:20 AM

Update
Exited
Exit Price
₹5,094.2
Net P&L
+₹975 (+0.79%)

Type
Sell
Instrument
DRREDDY
Entry Price
₹5,077.85
Price@Trade
₹5,077.85
Target Price
₹5,032
Stop Price
₹5,120
Valid Till
Jan 19, 2021 3:20 AM
Margin
₹50,778.5 approx for 10 Qty
Status
Exited
Exit Price
₹5,059.35
Net P&L
+₹185 (+0.36%)
1
Reply (2)
See all replies
Chaitu @chaitu-ryyR--C3v
Jan 19 3:10 AM

Update
Exited
Exit Price
₹5,059.35
Net P&L
+₹185 (+0.36%)
Dharun Invester @dharun
Jan 19 4:46 AM

Yes That's Analysis, Not trade with heavy quantity to increase your points. Good one
F
Reputation: 313 • Jan 19 2:42 AM

✅ POSITIONAL ✅
DR.REDDY BELOW 5040 TARGETS 5026, 5010, 4990, 4975 SL 5060
Like
Reply

PVR
ABOVE 1502
TARGETS 1510, 1520, 1530, 1540
SL 1485
.
.
COFORGE
BELOW 2500
TARGETS 2492, 2480, 2465, 2451
SL 2515
.
.
BAJAJ FIN
BELOW 4692
TARGETS 4680, 4660, 4645, 4625
SL 4712
.
.
DR.REDDY
BELOW 5040
TARGETS 5026, 5010, 4990, 4975
SL 5060
.
.
IBULHSG FIN
BELOW 21...
Read more...
1
Reply
N
Reputation: 10,359 • Jan 18 4:58 AM
Dr. Reddy’s Laboratories Q3 PAT May Dip 2% YoY To Rs. 781.6 Cr: Prabhudas Lilladher
Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.
Moneycontrol
Like
Reply
R
Reputation: 2,347 • Jan 18 11:00 AM

Axis Direct target on DRREDDY
Date: 18-Jan-21 Broker: Axis Direct Price @ Call: 5239.11 Target: 6200 Potential: 0.18% Recommendation: BUY
1
Reply

Type
Buy
Instrument
DRREDDY JAN21 5050 PE
Entry Price
₹132.3
Price@Trade
₹132.3
Target Price
₹150
Stop Price
₹120
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹16,537.5 approx for 125 Qty
Status
Exited
Exit Price
₹137.7
Net P&L
+₹675 (+4.08%)
Like
Reply (1)
See all replies

Update
Exited
Exit Price
₹137.7
Net P&L
+₹675 (+4.08%)

Dr. Reddy's has received DCGI approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India
1
Reply
A
Reputation: 8,546 • Jan 15 8:11 AM

Type
Buy
Instrument
DRREDDY JAN21 5300 CE
Entry Price
₹141.6
Price@Trade
₹141.6
Target Price
₹180
Stop Price
₹120
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹17,700 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹120
Net P&L
-₹2,700 (-15.25%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Jan 18 2:51 AM

Update
Stoploss Hit
Exit Price
₹120
Like
Reply
A
Reputation: 8,546 • Jan 15 6:46 AM

Type
Buy
Instrument
DRREDDY JAN21 5300 CE
Entry Price
₹152
Price@Trade
₹152
Target Price
₹200
Stop Price
₹140
Valid Till
Jan 28, 2021 3:20 AM
Margin
₹19,000 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹140
Net P&L
-₹1,500 (-7.89%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Jan 15 7:37 AM

Update
Stoploss Hit
Exit Price
₹140
V
Reputation: -4,747 • Jan 15 6:12 AM

Type
Buy
Instrument
DRREDDY JAN21 FUT
Entry Price
₹5,276
Price@Trade
₹5,272.7
Target Price
₹5,330
Stop Price
₹5,230
Valid Till
Jan 15, 2021 3:20 AM  Jan 22, 2021 3:20 AM
Margin
₹129,099.84 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹5,230
Net P&L
-₹5,750 (-4.45%)
Educational
Like
Reply (3)
See all replies
TrackerBot @trackerbot
Jan 15 6:15 AM

Update
Trade Entered
Entry Price
₹5,276
Vishv @vishv
Jan 15 7:13 AM

Update
Time Extended
Price @ Update
₹5,269.5
Original Time
Jan 15, 2021 3:20 AM
New Time
Jan 22, 2021 3:20 AM
TrackerBot @trackerbot
Jan 15 7:41 AM

Update
Stoploss Hit
Exit Price
₹5,230
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-Jan-21Axis DirectBuy6,200
    12-Jan-21SharekhanBuy6,500
    27-Nov-20Nirmal BangBuy5,648
    29-Oct-20Prabhudas LilladherBuy5,964
    29-Oct-20Nirmal BangBuy5,737
    DRREDDY Brokerage Price Target
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jan 21511051385033.95052.2
    Jan 205102.35159.755065.055080.65
    Jan 1950885104.955036.555088.9
    Jan 1852315237.9550355052.1
    Jan 15531553155195.65212.8
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹5,224.97
    30 Day Moving Average₹5,179.44
    50 Day Moving Average₹5,042.37
    100 Day Moving Average₹4,942.1
    200 Day Moving Average₹4,465.43
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY - Recent News

    keyboard_arrow_down
    NewsBot
    Jan 18 4:58 AM
    Dr. Reddy’s Laboratories Q3 PAT May Dip 2% YoY To Rs. 781.6 Cr: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Jan 13 7:58 AM
    Buy Dr Reddy’s Laboratories: Target Of Rs 6500: Sharekhan
    Moneycontrol
    NewsBot
    Jan 12 10:43 AM
    Four More COVID-19 Vaccines In Pipeline In India; Check Details Here
    Moneycontrol
    NewsBot
    Jan 11 3:48 AM
    Dr Reddy's Gets DSMB Nod To Conduct Phase-3 Trial Of Sputnik Covid-19 Vaccine In India
    Moneycontrol
    NewsBot
    Jan 11 11:13 AM
    Mumbai Airport To Handle Over Half Of SII's Covishield Vaccine
    Moneycontrol
    NewsBot
    Jan 6 8:23 AM
    SpiceJet Gets Ready To Distribute COVID-19 Vaccines, With Over A Dozen MoUs Under Its Belt
    Moneycontrol
    NewsBot
    Dec 22, 2020 6:58 AM
    Dr Reddy's Seeks Approval From Health Canada For Favipiravir
    Moneycontrol
    NewsBot
    Dec 21, 2020 3:13 AM
    Russia Will Jointly Produce Sputnik V Vaccine For COVID-19 With India: Russian Envoy Nikolay Kudashev
    Moneycontrol
    NewsBot
    Dec 7, 2020 1:48 AM
    This Is How DBT Is Helping Companies Accelerate Development Of COVID-19 Vaccine
    Moneycontrol
    NewsBot
    Dec 2, 2020 6:53 AM
    Dr Reddy’s Laboratories shares gain as firm commences clinical trials for Sputnik V vaccine
    Moneycontrol
  • DRREDDY - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020